Supply Chain

Safeguarding the Global Supply of Medicines Including Biologics

Safeguarding the Global Supply of Medicines Including Biologics

Today, many critical, life-saving medicines go through a complex global supply chain before ever reaching the patient. USP’s public standards play important roles throughout that supply chain. Learn more.

Share

Our Concerns Regarding Congressional Proposal to Discard Public Quality and Safety Standards for Biologics

Biologics Standards Proposal

For a hundred years, federal law has required that all drugs adhere to public quality standards—part of ensuring safety and protecting the public’s health. Language that would exempt biologics, including biosimilars, from adhering to the same public quality standards as other prescription medicines was recently added to the FDA and NIH Workforce Authorities Modernization Act. Learn about the potential impact this biologics quality exemption may have on competition, product development, and the public's confidence in biologics and biosimilars.

Share

A Multi-Sectorial Approach to Ensuring Medical Product Quality & Supply Chain Integrity

USP Contributes to APEC Initiative to Ensure Medical Product Quality & Supply Chain Integrity

Learn about USP's involvement in the APEC Life Sciences Innovation Forum and how this group is improving access to quality medical products by helping Asian-Pacific economies prevent, detect and respond to spurious, substandard, falsified, falsely-labelled and counterfeit products in their supply chains.

Share

Pages